PCLAF and myeloid sarcoma: For example, comparison of 165 Japanese patients diagnosed with clinically definite MS and 245 healthy controls demonstrated that the frequency of the missense mutation A224D, which impairs PAF-PAF receptor (PAFR) signaling, was significantly higher in MS patients (21.0%) than in healthy controls (13.5%).